Literature DB >> 24631739

Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma.

Jessica Rueff1, Michael Medinger1, Dominik Heim1, Jakob Passweg1, Martin Stern2.   

Abstract

Rapid immune reconstitution--particularly of natural killer cells (NK cells)--after allogeneic hematopoietic stem cell transplantation (HSCT) is associated with protection from relapse. Whether such an association also exists after autologous stem cell transplantation is less clear. We retrospectively assessed lymphocyte subsets after autologous HSCT in 114 patients and correlated lymphocyte recovery with outcome. CD8 T cell and NK cell counts recovered rapidly to pretransplantation levels, whereas B cell and CD4 T cell recovery were delayed. Compared with patients with low NK cells (<100/uL), high NK cell count at 1 month after HSCT was associated with significantly prolonged progression-free survival: for NK cells 100 to 200/uL hazard ratio [HR], .33 (95% confidence interval [CI]; .16 to .80; P = .004); for NK cells > 200/μL HR, .27 (95% CI, .13 to .58; P = .001). No significant protective effects were associated with rapid recovery of any other lymphocyte subset. None influenced overall survival (OS) or time to next treatment. Early NK cell recovery is associated with better progression-free survival after autologous HSCT. The failure to detect an effect on OS might be due to the salvage strategies available to these patients.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autologous stem cell transplantation; Natural killer cells; Plasma cell myeloma

Mesh:

Year:  2014        PMID: 24631739     DOI: 10.1016/j.bbmt.2014.03.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  33 in total

1.  IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.

Authors:  Cristina Puig-Saus; Giulia Parisi; Angel Garcia-Diaz; Paige E Krystofinski; Salemiz Sandoval; Ruixue Zhang; Ameya S Champhekar; James McCabe; Gardenia C Cheung-Lau; Nhat A Truong; Agustin Vega-Crespo; Marie Desiles S Komenan; Jia Pang; Mignonette H Macabali; Justin D Saco; Jeffrey L Goodwin; Brad Bolon; Christopher S Seet; Amelie Montel-Hagen; Gay M Crooks; Roger P Hollis; Beatriz Campo-Fernandez; Daniela Bischof; Kenneth Cornetta; Eric H Gschweng; Celia Adelson; Alexander Nguyen; Lili Yang; Owen N Witte; David Baltimore; Begonya Comin-Anduix; Donald B Kohn; Xiaoyan Wang; Paula Cabrera; Paula J Kaplan-Lefko; Beata Berent-Maoz; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2018-11-08       Impact factor: 12.531

2.  Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts.

Authors:  Harsh Shah; Seongho Kim; Paramveer Singh; Asif Alavi; Voravit Ratanatharathorn; Lois Ayash; Joseph Uberti; Abhinav Deol
Journal:  Am J Hematol       Date:  2019-12-11       Impact factor: 10.047

3.  T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.

Authors:  David J Chung; Katherine B Pronschinske; Justin A Shyer; Sneh Sharma; Samantha Leung; Shane A Curran; Alexander M Lesokhin; Sean M Devlin; Sergio A Giralt; James W Young
Journal:  Cancer Immunol Res       Date:  2015-10-13       Impact factor: 11.151

4.  Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation.

Authors:  A Kansagra; D J Inwards; S M Ansell; I N Micallef; P B Johnston; W J Hogan; S N Markovic; L F Porrata
Journal:  Bone Marrow Transplant       Date:  2017-10-16       Impact factor: 5.483

Review 5.  NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect?

Authors:  Catharina H M J Van Elssen; Stefan O Ciurea
Journal:  Int J Hematol       Date:  2017-12-01       Impact factor: 2.490

6.  In vivo expansion of a CD9+ decidual-like NK cell subset following autologous hematopoietic stem cell transplantation.

Authors:  Ane Orrantia; Enrique Vázquez-De Luis; Gabirel Astarloa-Pando; Iñigo Terrén; Ainhoa Amarilla-Irusta; Diego Polanco-Alonso; Carmen González; Alasne Uranga; Tomás Carrascosa; Juan J Mateos-Mazón; Juan C García-Ruiz; Sergio Callejas; Ana Quintas; Ana Dopazo; Olatz Zenarruzabeitia; Francisco Borrego
Journal:  iScience       Date:  2022-09-28

Review 7.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

Review 8.  BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.

Authors:  Sarah A Holstein; Hervé Avet-Loiseau; Theresa Hahn; Christine M Ho; Jens G Lohr; Nikhil C Munshi; Bruno Paiva; Marcelo C Pasquini; Joseph D Tario; Saad Z Usmani; Paul K Wallace; Katja Weisel; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2017-12-11       Impact factor: 5.742

9.  Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT.

Authors:  Christine M Ho; Philip L McCarthy; Paul K Wallace; Yali Zhang; Ahmad Fora; Patrick Mellors; Joseph D Tario; Benjamin L S McCarthy; George L Chen; Sarah A Holstein; Sophia R Balderman; Xuefang Cao; Bruno Paiva; Theresa Hahn
Journal:  Blood Adv       Date:  2017-06-20

Review 10.  Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.

Authors:  Liu Zhaoyun; Fu Rong
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.